Lytic Bone Metastasis in a Case with Primary Breast Lymphoma by Yasemin Benderli Cihan et al.
Cancer and Oncology Research 3(4): 45-48, 2015 http://www.hrpub.org 
DOI: 10.13189/cor.2015.030401 
Lytic Bone Metastasis in a Case with Primary       
Breast Lymphoma 
Yasemin Benderli Cihan1,*, Alaettin Arslan1, Mehmet Faik Cetindag2 
1Kayseri Education and Research Hospital, Department of Radiation Oncology, Turkey 
2Ankara Education and Research Hospital, Department of Radiation Oncology, Turkey 
  
Copyright © 2015 by authors, all rights reserved. Authors agree that this article remains permanently open access under the 
terms of the Creative Commons Attribution License 4.0 International License 
Abstract  Bone metastasis alone without involvement of 
bone marrow is rarely seen in primary breast lymphoma 
(PBL). It has a poor prognosis. A 64-years old woman was 
diagnosed as high-grade PBL T type. The patient received 6 
sessions of chemotherapy with a diagnosis of stage IIAE 
PBL. The patient achieved remission and was followed for 
12 years. She underwent surgery due to fracture at lower half 
of right femur. Palliative radiotherapy (30 Gy) was given to 
right femur. Here, we presented a patient with high-grade 
PBL T type developed lytic bone metastasis without bone 
marrow involvement. 
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1. Introduction 
Primary breast lymphoma is defined as lymphoma at 
breast or axillary region alone without involvement at any 
other region of the body. It comprises 0.04-0.5% of all breast 
cancers and 1.7-2.2% of extra-nodal lymphomas [1]. It has 
an increasing incidence by time. It is usually seen at sixth 
decade and is more frequent in female gender. The most 
common histological type is diffuse, large B-cell lymphoma. 
High-grade T type is seen in rare cases. Bone marrow 
involvement is present in 13% of all cases of primary breast 
lymphoma. Generally, Ann Arbor staging system is used for 
staging [2-4].  
There is no established standard therapy for PBL. As in 
the lymphomas at other regions, it is treated by using 
anthracycline-based systemic chemotherapy and 
radiotherapy [1,5,6]. Five-year survival rate varies between 
45% and 70%. Its prognosis is similar to those seen at other 
regions and depends on cellular type, clinical stage and 
treatment [1, 3,5]. 
In this manuscript, we presented clinical characteristics, 
therapeutic approaches and outcomes in a patient who had 
been treated with high-grade, PBL T type with lytic bone 
metastasis without bone marrow involvement. 
2. Case Report 
A 64-years old woman presented with a palpable mass in 
June, 2001. Left modified radical mastectomy was 
performed, as fine-needle biopsy was reported as malign 
pathology. On immunohistochemical evaluation, there was 
diffuse LCA and CD 45RO staining and positive CD 79 
staining in large areas in the surgical specimen. In surgical 
specimen, there was an involvement in one axillary lymph 
node. Thus, the case was considered as high-grade T cell 
lymphoma based on histopathological appearance and 
staining characteristics (Figure 1). No regional or distant 
organ involvement was detected on physical examination 
and radiological evaluations (computerized tomography 
scans of thorax, neck, brain and abdominal). Bone marrow 
biopsy was interpreted as normal. Since there was no disease 
finding in other regions, the patient was considered as 
primary breast lymphoma. The patient received 6 session of 
CHOP regime (cyclophosphamide, doxorubicin, vincristine, 
prednisone) with a diagnosis of stage IIAE PBL. Control 
examinations were normal after primary treatment. No 
recurrence or metastasis was detected. 
 
Figure 1.  Hematoxylin and eosin-stained section shows infiltrate of 
atypical lymphocytes with normal breast tissue being identified (100x).  
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A fracture at distal half of right femur developed 12 years 
after diagnosis (Figure 2). The patient was consulted to our 
department after surgery due to fracture. Perioperative bone 
marrow aspiration was considered as normocellular. On 
physical examination, no lymphadenopathy was detected at 
cervical and axillary region. Respiratory and cardiovascular 
examinations were considered as normal. On CT scans of 
neck, thorax or abdomen, no lymphadenopathy or mass was 
detected. On whole-body bone scintigraphy, increased 
uptake was detected at distal half of right femur. Palliative 
radiotherapy (overall 30 Gy in 10 fractions) was given to 
distal half of right femur 4 weeks after surgery.  CBC was 
found as normal after radiotherapy. Biochemical parameters 
other than LDH (478 IU; normal range: 140-280 IU) was 
normal. On PET-CT scan, intense FDG uptake was detected 
in multiple lymph nodes at right distal paratracheal area, 
aortopulmonary window and bilateral hilar area (largest 
being 14x9 mm in size), right obturator and inguinal areas 
(largest being 21x12 mm in size) were detected, while 
hyper-intense FDG uptake at distal half of right femur and 
proximal metaphysodiaphyseal area area of left tibia in 
musculoskeletal scanning. No involvement was found at 
central nervous system (CNS) (Figure 3). Chemotherapy was 
scheduled as organ involvement was predominant. 
 
Figure 2.  Right femur pathologic fracture 
 
Figure 3.  PET-CT scan intense FDG uptake 
3. Discussion 
The behavior of primary breast lymphoma is similar to the 
lymphomas rising from other regions with identical age and 
histology. Majority of patients present with unilateral, 
painless, palpable mass. It is usually encountered at upper 
outer quadrant of right breast and it is more frequent in 
female gender. B symptoms are lacking in most cases 
(82-96%) [1,6,7]. Diagnostic approach should involve 
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complete blood count, biochemical parameters, LDH 
measurement, bone marrow aspiration/biopsy, 
mammography, CT scans of thorax, abdomen and pelvis, 
and PET-CT, if indicated. Role of mammography is limited 
in radiological diagnosis. Sonographic evaluation has more 
specific characteristics [7,8,9]. Our case presented with 
palpable mass localized as upper outer quadrant of right 
breast. She had no B symptoms. 
Diffuse, large B cell lymphoma is most commonly 
observed histological type. In addition, follicular lymphoma, 
MALT lymphoma and Burkitt lymphoma can also be 
observed. T cell type is seen in rare cases [3-9]. In a study by 
Kuper-Hommel et al., it was reported that incidence of 
diffuse, large B cell lymphoma varied between 45% and 79% 
[10]. Authors also reported that this type is generally 
unilateral and often observed in middle-age women [10]. In a 
meta-analysis including 450 cases, Jennings et al. reported 
that the most common type was diffuse, large cell lymphoma 
with a frequency of 53% [4]. In our case, tumor histology 
was compatible with high-grade T cell lymphoma and 
immunohistochemical staining supported T cell subtype. 
Management of primary breast lymphoma is similar to 
those in other lymphoma types, including surgery, 
chemotherapy, and radiotherapy [3-6]. As primary breast 
lymphoma usually tends to persist confined, mastectomy 
isn’t recommended in these patients and breast-sparing 
surgery is preferred in such cases other than those with bulky 
disease and aggressive histopathology [4,10-13]. In a 
systematic review on 465 patients, Jenning et al. reported 
that mastectomy didn’t improve survival and local control in 
PBL [4]. 
When radiotherapy and chemotherapy alone were 
compared to chemoradiotherapy, there was a significant 
difference in disease-free and overall survival rates in favor 
of combined therapy. In a study on 96 patients with early 
stage PBL (stage I and II) by Aviles et al., radiotherapy (45 
Gy) was given to 30 patients while chemotherapy to 32 
patients and combined treatment to 30 patients (30 Gy). 
Complete response was achieved in 20 patients in 
radiotherapy arm; in 19 patients in chemotherapy arm; and in 
30 patients in combined treatment arm. Ten-year 
disease-free survival rates were 50%, 57% and 83% whereas 
overall survival rates were 50%, 50% and 76%, respectively 
[4]. A study on 204 patients by Ryan et al., a multicenter 
study on 36 patients by Martinelli et al . reported similar 
outcomes [3,7,8]. In a single-center study on 45 patients by 
Validire et al., histological type was diffuse, large B cell 
lymphoma in 38 patients (83%). Other histological types 
included lymphocytic lymphoma in 2 patients, grade I 
follicular NHL in 3 patients, MALT lymphoma in one 
patient and grade IIIB follicular lymphoma in another patient. 
In that study, authors analyzed 38 patients with diffuse, large 
B cell lymphoma and classified 37 patients with available 
data according to International Prognostic Index as follows: 
19 patients (51%) in low-risk group, 5 patients (14%) in 
low-moderate risk group, 6 patients (16%) in moderate-high 
risk group, and 7 patients (19%) in high risk group. Authors 
observed that there was worsening in 18 patients (47%) and 
worsening in CNS in 3 patients during median follow-up of 
96-months. Five-year disease-free and overall survival rates 
were calculated as 54% and 61%, respectively [5]. As a 
result, studies concluded that chemotherapy alone or 
chemotherapy plus radiotherapy should be given to patients 
with moderate and high grade disease. It was suggested that 
radiotherapy improved local control with recommended dose 
of 40 Gy (35-50 Gy). Today, CHOP is most commonly used 
chemotherapy regime in such patients [4,9,12,13]. It is 
unclear whether rituximab should be added [9].  In our case, 
modified radical mastectomy was performed when 
fine-needle aspiration biopsy was reported as malign disease. 
Excisional biopsy could prevent unnecessary mastectomy, if 
performed in our case. The patient received 6 sessions CHOP 
due to detection of axillary involvement in pathological 
evaluation. Disease-free survival was 12 years in our patient 
although no radiotherapy was given. 
In the literature, Validire et al. reported bone marrow 
involvement of PBL [5]. To best of our knowledge, there is 
no information regarding bone metastasis. PBL is considered 
within NHL group. Lymphamatous involvement of 
musculoskeletal system is rare in NHLs.  Lymphomas are 
not typically associated with lytic bone lesions. Lytic bone 
metastasis is generally seen metastatic breast cancer and 
multiple myeloma. In general, bone metastasis in lymhoma 
is observed following bone marrow involvement and seen at 
femur and pelvis. The primary complaint is pain in such 
patients. Patients suffer from acute, rapidly worsening pain 
which doesn’t relieve with rest. Pathological fractures in this 
area results in impaired mobility, dysfunction and decreased 
quality of life [14].   
 Our case presented with pathological fracture after 
prolonged disease-free period. Bone marrow aspiration 
biopsy was normal. There was intense FDG uptake on 
PET-CT and increased pathological activity uptake in 
whole-body bone scintigraphy. 
4. Conclusions 
High-grade, primary breast lymphoma T type with lytic 
bone metastasis without bone marrow involvement is rarely 
encountered in lymphoma. Chemotherapy or radiotherapy is 
recommended in the treatment 
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